Publication

Pharmacological approaches to optimize TB treatment: An individualized approach

Zuur, M., 2018, [Groningen]: Rijksuniversiteit Groningen. 225 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 768 KB, PDF document

  • Chapter 1

    Final publisher's version, 1 MB, PDF document

  • Chapter 2

    Final publisher's version, 1 MB, PDF document

  • Chapter 3a

    Final publisher's version, 1 MB, PDF document

  • Chapter 3b

    Final publisher's version, 1 MB, PDF document

  • Chapter 4

    Final publisher's version, 1 MB, PDF document

  • Chapter 5a

    Final publisher's version, 1 MB, PDF document

  • Chapter 5b

    Final publisher's version, 1 MB, PDF document

  • Chapter 6a

    Final publisher's version, 1 MB, PDF document

  • Chapter 6b

    Final publisher's version, 1 MB, PDF document

  • Chapter 6c

    Final publisher's version, 1 MB, PDF document

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

  • Summary

    Final publisher's version, 1 MB, PDF document

  • Samenvatting

    Final publisher's version, 912 KB, PDF document

  • Dankwoord

    Final publisher's version, 1 MB, PDF document

  • About the author

    Final publisher's version, 1 MB, PDF document

  • Complete thesis

    Final publisher's version, 5 MB, PDF document

  • Propositions

    Final publisher's version, 870 KB, PDF document

  • Marlies Zuur
In order to improve tuberculosis treatment, an individualized approach is necessary. We plead for individualized dosing based on drug exposure
measured in blood – Therapeutic Drug Monitoring (TDM).To measure exposure reliably, multiple blood samples are needed, which is burdening
and inconvenient for the patients. Dried blood spot sampling (DBS), a method that uses blood from a finger prick– the technique diabetes patients
use to control their blood sugar levels – is a more patient-friendly approach than multiple venous blood drawings, provided that the number of samplings
is not excessive. To minimize the number of blood samples, we established a limited sampling strategy for ertapenem. Ertapenem is a carbapenem
antibiotic that has not (yet) been accepted for tuberculosis treatment; we discuss the potential use of ertapenem for tuberculosis treatment. We also
studied fixed-dose combinations in combination with TDM. Individualization and fixed-dose may seem contradictive but we argue that TDM might
detect and correct treatment mistakes resulting from fixed dosing. Susceptibility of Mycobacterium tuberculosis has traditionally been reported as
either susceptible or resistant. In this thesis we propose adding a shade of grey; intermediate susceptibility that would represent a
dose-dependent susceptibility category. We studied whether patients with M. tuberculosis isolates with intermediate susceptibility could be treated with
a higher dose of anti-tuberculosis drugs and if so, if this approach would be cost-effective. We conclude that TDM is useful and feasible,
but more research is needed to address as yet unanswered questions.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date19-Nov-2018
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-034-0998-6
Electronic ISBNs978-94-034-0997-9
Publication statusPublished - 2018

View graph of relations

Download statistics

No data available

ID: 66426439